Literature DB >> 15314246

Novel approaches to models of Alzheimer's disease pathology for drug screening and development.

Laura Shaughnessy1, Beth Chamblin, Lori McMahon, Ayyappan Nair, Mary Beth Thomas, John Wakefield, Frank Koentgen, Ram Ramabhadran.   

Abstract

Development of therapeutics for Alzheimer's disease (AD) requires appropriate cell culture models that reflect the errant biochemical pathways and animal models that reflect the pathological hallmarks of the disease as well as the clinical manifestations. In the past two decades AD research has benefited significantly from the use of genetically engineered cell lines expressing components of the amyloid-generating pathway, as well as from the study of transgenic mice that develop the pathological hallmarks of the disease, mainly neuritic plaques. The choice of certain cell types and the choice of mouse as the model organism have been mandated by the feasibility of introduction and expression of foreign genes into these model systems. We describe a universal and efficient gene-delivery system, using lentiviral vectors, that permits the development of relevant cell biological systems using neuronal cells, including primary neurons and animal models in mammalian species best suited for the study of AD. In addition, lentiviral gene delivery provides avenues for creation of novel models by direct and prolonged expression of genes in the brain in any vertebrate animal. TranzVector is a lentiviral vector optimized for efficiency and safety that delivers genes to cells in culture, in tissue explants, and in live animals regardless of the dividing or differentiated status of the cells. Genes can also be delivered efficiently to fertilized single-cell-stage embryos of a wide range of mammalian species, broadening the range of the model organism (from rats to nonhuman primates) for the study of disease mechanism as well as for development of therapeutics. Copyright 2004 Humana Press Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15314246     DOI: 10.1385/JMN:24:1:023

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  32 in total

Review 1.  Slipping through the door: HIV entry into the nucleus.

Authors:  Michael P Sherman; Warner C Greene
Journal:  Microbes Infect       Date:  2002-01       Impact factor: 2.700

Review 2.  Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites.

Authors:  S Vagner; B Galy; S Pyronnet
Journal:  EMBO Rep       Date:  2001-10       Impact factor: 8.807

3.  Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695.

Authors:  M A Chishti; D S Yang; C Janus; A L Phinney; P Horne; J Pearson; R Strome; N Zuker; J Loukides; J French; S Turner; G Lozza; M Grilli; S Kunicki; C Morissette; J Paquette; F Gervais; C Bergeron; P E Fraser; G A Carlson; P S George-Hyslop; D Westaway
Journal:  J Biol Chem       Date:  2001-03-15       Impact factor: 5.157

4.  Strain-dependent differences in the efficiency of transgenic mouse production.

Authors:  Anna B Auerbach; Rada Norinsky; Weilan Ho; Kasia Losos; Qiuxia Guo; Samprit Chatterjee; Alexandra L Joyner
Journal:  Transgenic Res       Date:  2003-02       Impact factor: 2.788

Review 5.  Lentiviruses as gene transfer agents for delivery to non-dividing cells.

Authors:  L Naldini
Journal:  Curr Opin Biotechnol       Date:  1998-10       Impact factor: 9.740

6.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.

Authors:  L Naldini; U Blömer; F H Gage; D Trono; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with the deletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene.

Authors:  K Ishii; K Ii; T Hasegawa; S Shoji; A Doi; H Mori
Journal:  Neurosci Lett       Date:  1997-05-30       Impact factor: 3.046

8.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.

Authors:  D Games; D Adams; R Alessandrini; R Barbour; P Berthelette; C Blackwell; T Carr; J Clemens; T Donaldson; F Gillespie
Journal:  Nature       Date:  1995-02-09       Impact factor: 49.962

Review 9.  Genetically engineered mouse models of neurodegenerative diseases.

Authors:  Philip C Wong; Huaibin Cai; David R Borchelt; Donald L Price
Journal:  Nat Neurosci       Date:  2002-07       Impact factor: 24.884

10.  The majority of G0 transgenic mice are derived from mosaic embryos.

Authors:  C B Whitelaw; A J Springbett; J Webster; J Clark
Journal:  Transgenic Res       Date:  1993-01       Impact factor: 2.788

View more
  3 in total

Review 1.  Gene-environment interplay in neurogenesis and neurodegeneration.

Authors:  Tomás Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

2.  Attenuated food anticipatory activity and abnormal circadian locomotor rhythms in Rgs16 knockdown mice.

Authors:  Naoto Hayasaka; Kazuyuki Aoki; Saori Kinoshita; Shoutaroh Yamaguchi; John K Wakefield; Sachiyo Tsuji-Kawahara; Kazumasa Horikawa; Hiroshi Ikegami; Shigeharu Wakana; Takamichi Murakami; Ram Ramabhadran; Masaaki Miyazawa; Shigenobu Shibata
Journal:  PLoS One       Date:  2011-03-09       Impact factor: 3.240

3.  An over expression APP model for anti-Alzheimer disease drug screening created by zinc finger nuclease technology.

Authors:  Xiaojing Zhang; Hui Li; Yiqing Mao; Zhixin Li; Rong Wang; Tingting Guo; Ling Jin; Rongjing Song; Wei Xu; Na Zhou; Yizhuang Zhang; Ruobi Hu; Xi Wang; Huakang Huang; Zhen Lei; Gang Niu; David M Irwin; Huanran Tan
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.